Immunoadsorption therapy is an experimental treatment option for dilated cardiomyopathy that requires confirmation by a placebo-controlled multicenter study.
Dilated cardiomyopathy is a common myocardial disease characterized by ventricular chamber enlargement and systolic dysfunction that result in heart failure. In addition to genetic predisposition, viral infection and myocardial inflammation play a causal role in the disease process of dilated cardiomyopathy. Experimental and clinical studies suggest that activation of the humoral immune system, with production of circulating cardiac autoantibodies, plays an important functional role in the development and progression of cardiac dysfunction in patients with dilated cardiomyopathy. Small open-controlled studies showed that removal of circulating antibodies by immunoadsorption results in improvement of cardiac function and decrease in myocardial inflammation. At present, immunoadsorption is an experimental treatment option for improvement of cardiac function - therapy that calls for confirmation by a placebo-controlled multicenter study.
Felix et al. (Sat,) conducted a review in Dilated cardiomyopathy. Immunoadsorption therapy was evaluated. Immunoadsorption therapy is an experimental treatment option for dilated cardiomyopathy that requires confirmation by a placebo-controlled multicenter study.